Respiri : Copy of investor presentation

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on Respiri's current expectations, estimates and projections about the industry in which Respiri operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward-looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services.

These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of Respiri, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. Respiri cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Respiri only as of the date of this release.

The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. Respiri will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

1

1

CAPITAL STRUCTURE

Market Capitalisation - 26 Apr 2022

Closing Share Price - 26 Apr 2022 Shares on Issue

Management Performance Options*

Cash Balance - 31 Dec 2021

Wheezo stock on hand - 31 Dec 2021

Projected Cash Burn - Q2 & Q3 FY22

* Average strike price $0.187

MAJOR SHAREHOLDERS (APRIL 2022)

A$36.9M A$0.051

• 723M Indication

• 174.5M Addressable Market - USA

• $5.1M Business model

22k units (A$1.4M) A$550k / month

Investment Holdings Pty Ltd 9.2%

Netwealth Investments Limited 4.0%

Richards Family 3.3%

Directors 2.4%

Peter Braun 2.2%

Top 20 Shareholders 31.33

OPERATIONAL SNAPSHOT

Market drivers (USA)FDA / CE / TGA Wheeze detection ~US$40B; CAGR 30%+ RPM* provider partners Reimbursements

BOARD OF DIRECTORS & ADVISORS

Respiratory disorders are a significant burden to healthcare systems globally, however, payors in the United States understand the importance of RPM services and pay for it.

1. Asthma control tests which are subjective, relying on unreliable patient self-assessments

2. Digital spirometry devices which are difficult for patients to use in supervised environments & extremely difficult remotely.

1 in 131

living with asthma

1.6 million3

ED visits with asthma

$8,2384

cost per in-patient medical event

1 in 202

living with COPD

873k2

ED visits with COPD

$27,5974

cost per in-patient medical event

(1)https://www.cdc.gov/nchs/fastats/asthma.htm

(2)https://www.cdc.gov/nchs/fastats/copd.htm

(3)https://www.cdc.gov/asthma/asthma_stats/asthma-ed-visits_2010-2018.html

(4)https://www.cdc.gov/mmwr/volumes/69/wr/pdfs/mm6926-H.pdf

This is an excerpt of the original content. To continue reading it, access the original document here.